Syros Pharmaceuticals, Inc.
SYRS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $140 | $167 | $92 | $174 |
| Short-Term Investments | $0 | $35 | $38 | $0 |
| Receivables | $0 | $2 | $3 | $2 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $7 | $3 | $2 |
| Total Curr. Assets | $145 | $211 | $137 | $179 |
| Property Plant & Equip (Net) | $19 | $25 | $27 | $30 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $2 | $3 | $13 | $3 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $5 | $6 | $2 |
| Total NC Assets | $23 | $33 | $46 | $35 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $168 | $244 | $183 | $213 |
| Liabilities | – | – | – | – |
| Payables | $12 | $6 | $4 | $4 |
| Short-Term Debt | $9 | $2 | $2 | $3 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $4 | $10 | $12 |
| Other Curr. Liab. | $16 | $18 | $16 | $9 |
| Total Curr. Liab. | $37 | $31 | $32 | $29 |
| LT Debt | $53 | $62 | $63 | $64 |
| Deferred Rev, NC | $0 | $0 | $0 | $10 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $62 | $24 | $3 | $20 |
| Total NC Liab. | $115 | $86 | $66 | $94 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $21 | $23 | $25 | $27 |
| Total Liabilities | $152 | $117 | $98 | $123 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$723 | -$558 | -$464 | -$377 |
| AOCI | $0 | $0 | -$0 | $0 |
| Other Equity | $739 | $686 | $549 | $468 |
| Total Equity | $17 | $128 | $85 | $91 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $168 | $244 | $183 | $213 |
| Net Debt | -$77 | -$104 | -$27 | -$106 |